PRO-BANTHINE
LOE ApproachingNDAORALTABLET
Approved
Apr 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRO-BANTHINE is an oral tablet small molecule approved in 1953 with an unknown mechanism of action and indication profile. The product is a legacy NDA currently approaching loss of exclusivity. Patient population and therapeutic application cannot be determined from available data.
LOE Approaching
With LOE approaching and minimal commercial data, the PRO-BANTHINE team likely operates in maintenance mode with limited investment in expansion or headcount growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE indicate PRO-BANTHINE is a low-priority asset within Takeda's portfolio. Career growth on this product is limited; roles are likely focused on sustaining current market position rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on PRO-BANTHINE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.